Iain’s practice focuses on patent prosecution in the life sciences field. A cell biologist by background, he has particular experience in medical applications of the life sciences. His interests cover a number of challenging legal and technical areas, including: cell-based therapies (such as CAR-T and stem cells); personalised healthcare; therapeutic antibodies; wound healing therapies; and cancer treatments.
His client base ranges from start-ups to multinationals, with a particular focus on university research and technology transfer. He counts a number of highly regarded UK and overseas universities among his clients and is a member of the Association of University Technology Managers (regularly attending the AUTM Annual Meeting).
Iain aims to provide clear and pragmatic advice to his clients, guiding them through complex legal issues, and helping them use the patent system to meet their business aims. Having been in private practice for over 20 years, Iain has extensive experience in the development, growth and management of biotech-based patent portfolios. He has demonstrated expertise in drafting and prosecution of patent applications suitable for worldwide coverage, and able to provide high quality protection that stands up to competitor challenge or rigorous due diligence. He is familiar with many of the technical and legal problems that can arise in this complicated area, and with counselling clients through these.
Iain has been invited to speak on topics including: "Biotech patent drafting", "Patentability of stem cells” and “CAR-T cell therapy: filing trends, opportunities and challenges to patentability”.
First class (Honours) Cell Biology - University of Glasgow
Postgraduate Certificate in Intellectual Property - University of Manchester
June 14th 2021
November 4th 2020
October 16th 2019
Member of CIPA’s Life Sciences Committee
Produced CIPA CPD lecture on “Biotech patent drafting”
Produced CIPA CPD lecture on “Patentability of stem cells”
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …Event details
HGF Partner Dr Susan Keston and Senior Patent Attorney Dr Sofie McPherson will be presenting a webinar ‘How to capitalise on the 5G healthcare revolution’ on 25th May. This session will explore how 5G …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.